克拉屈滨-成人朗格汉斯综合征Cladribine therapy in adults with advanced Langerhans cell histiocytosis..pdfVIP

Leukemia Lymphoma, July 2013; 54(7): 1541–1543 © 2013 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.31092012.744454 LETTER TO THE EDITOR Cladribine therapy in adults with advanced Langerhans cell histiocytosis 1 2 1 1 1 Marian Schini , Polyzois Makras , George Kanakis , Michael Voulgarelis Gregory Kaltsas 1 Department of Pathophysiology, National University of Athens, Greece and 2Department of Endocrinology 3 and Diabetes, 251 Hellenic Air Force General Hospital, Athens, Greece 1 / 0 3 / 7 0 n o Langerhans cell histiocytosis (LCH) is a rare disease, characteristics, extent of disease, previous treatments and e n i particularly in adults, with an incidence of 1 – 2 cases per treatment side ef ects are summarized in Table I. Two c i d million [1]. Although LCH is caused by the proliferation patients (patients 3 and 5) were treated due to lung involve- e M f and ini ltration of organs by pathological Langerhans cells, ment. Patient 3, a 19-year-old man, was started on treat- o l the precise underlying pathology of the disease remains ment with vinblastine and prednisolone according to the o o h unknown [2]. h e clinical manifestations of the disease vary LCH III protocol. He received two cycles but the treatment c S y widely, since any organ can be af ected, the most common was abandoned due to recurrent pne